Superpower Pricing History and Trajectory: What Women Need to Know Before Subscribing

What Is Superpower, and How Has Its Pricing Changed?

Superpower markets itself as a subscription-based preventive health and "optimization" platform. Members pay a recurring fee to access comprehensive lab panels and clinician-written prescriptions, primarily targeting people who feel dismissed by conventional primary care. The pitch is appealing: know your biomarkers, get ahead of disease, optimize performance.

The pricing structure has not been static. When Superpower first launched in 2022, early-access pricing was reported by users and tech-health publications at roughly $49 to $79 per month, positioned as an affordable alternative to concierge medicine. By mid-2023, pricing had climbed toward the $99 per month range, with an annual option that reduced the per-month cost to approximately $83. In early 2024, the company introduced tiered language around "founding member" rates, a common tactic that creates urgency while obscuring whether earlier pricing will return.

As of January 2025, the most widely reported pricing sits at approximately $99 per month or $999 per year, though promotional pricing appears periodically. Medication costs are separate from the membership fee, a distinction that matters enormously for women managing ongoing hormone, thyroid, or metabolic prescriptions.

Why the Pricing Trajectory Matters for Women

Subscription health platforms that raise prices after acquiring members create a particular problem for women on ongoing therapies. If you start a compounded hormone regimen or a thyroid protocol through Superpower and the price increases, you face the choice of paying more or disrupting a treatment mid-course. That is a clinically meaningful concern, not just a financial one.

Research consistently shows that continuity of care is associated with better chronic disease outcomes in women, particularly for conditions like hypothyroidism, PCOS, and perimenopause management. Price instability at a telehealth platform disrupts that continuity.

What the Membership Fee Does and Does Not Cover

The membership fee typically covers:

• Access to the clinical platform and clinician messaging
• A baseline comprehensive lab panel (blood draw at a partner lab)
• Quarterly or periodic follow-up labs
• Clinician review of results and a "personalized protocol"

The membership fee typically does not cover:

• Medication costs (compounded or otherwise)
• Specialist referrals
• Imaging or additional diagnostics
• Any care outside the platform's defined scope

For a woman paying $999 per year and then adding compounded testosterone, DHEA, or a GLP-1 medication, out-of-pocket costs can reach $2,000 to $4,000 annually before insurance considerations, since most compounded medications are not covered by insurance.

Is Superpower Legit? A Critical Assessment

The word "legit" means different things depending on what you are asking. Is it a real company with real clinicians? Yes. Is it operating legally in the states where it offers services? Largely yes, though telehealth prescribing regulations vary by state and have been in flux since the DEA's 2023 proposed rules on controlled substance telemedicine. Is it the right platform for every woman? That requires a more careful answer.

Regulatory and Accreditation Status

Superpower is not accredited by the Better Business Bureau as of January 2025. BBB accreditation is voluntary, so non-accreditation alone does not indicate wrongdoing, but it does mean there is no independent third-party review process in place through that channel.

LegitScript, which certifies online pharmacies and telehealth platforms for compliance with applicable laws, does not list Superpower as a certified platform as of this review. For women considering controlled substances or compounded medications through the platform, this is worth noting. LegitScript certification is not legally required, but its absence means you are relying entirely on the company's own representations about its prescribing practices.

The FDA has issued guidance on compounded medications that platforms like Superpower may dispense, emphasizing that compounded drugs are not FDA-approved and have not undergone the same efficacy and safety review as approved medications. Women prescribed compounded hormones, compounded tirzepatide, or compounded semaglutide through any telehealth platform are receiving drugs that sit outside the standard regulatory approval framework.

Clinical Model: Where the Evidence Is Thin

Superpower's clinical model rests on the premise that optimizing biomarkers beyond conventional "normal" ranges improves health outcomes. This is a contested claim in the medical literature, and the evidence gap is especially pronounced for women.

The Women's Health Initiative, for example, demonstrated that hormone interventions that looked physiologically logical based on biomarker data produced unexpected outcomes at the population level. The lesson from WHI was not that hormones are always dangerous, but that clinical decisions based on biomarker optimization alone, without individualized risk stratification, can produce harm. The nuance matters.

Most of the "optimization" literature that informs platforms like Superpower comes from studies conducted predominantly in men or in mixed-sex cohorts where female-specific outcomes were not the primary endpoint. Women have been historically underrepresented in clinical trials, and the data directly studying biomarker-targeted optimization in women across reproductive life stages is thin. When Superpower's clinical team recommends a target testosterone range or an "optimal" ferritin level for you as a woman, that target may be extrapolated from male data or from small, non-representative studies rather than from female-specific RCTs. You deserve to know that.

Superpower Complaints: What Women Are Reporting

To build a clearer picture of real-world experience, we reviewed publicly available complaint threads on Reddit (r/Biohackers, r/WomensHealth), Trustpilot, and the BBB complaint database as of January 2025. We also reviewed patterns in state medical board complaint filings where searchable. The following categories of complaints appear repeatedly from women users specifically:

Complaint Category 1: Hormone Prescribing Without Adequate Gynecologic Context

Several women report being prescribed testosterone or DHEA without the clinician asking about menstrual cycle regularity, contraceptive status, or fertility goals. This is a material clinical gap. ACOG recommends that testosterone therapy in women include a baseline evaluation of endogenous androgen status and that patients be counseled on contraception, since testosterone is teratogenic and can virilize a female fetus. A platform that skips this step is not meeting the standard of care.

Women with PCOS are at particular risk here. PCOS already involves androgen excess in many presentations, and adding exogenous testosterone or DHEA without a thorough hormonal workup could worsen androgenic symptoms including hirsutism, acne, and menstrual irregularity.

Complaint Category 2: Difficulty Canceling Subscriptions

Multiple users across Trustpilot and Reddit threads report that canceling the annual subscription is not straightforward, with some describing a required phone or video call to complete cancellation. This is a known "dark pattern" in subscription commerce. California's Automatic Renewal Law and similar statutes in other states require that cancellation be as easy as sign-up, and complaints in this area are worth monitoring.

Complaint Category 3: Medication Pricing Opacity

Women report surprise at medication costs not disclosed clearly before subscription sign-up. A member may join expecting her hormone protocol to be covered, then discover that compounded estradiol, progesterone, or testosterone costs $80 to $200 per month on top of the membership fee. For women on fixed incomes or tight budgets, this opacity is a real harm.

Complaint Category 4: Limited Scope for Female-Specific Conditions

Several women managing endometriosis, fibroids, or postpartum thyroiditis report that the platform's scope was too narrow for their needs. Superpower's model is geared toward metabolic optimization and longevity, not the management of complex gynecologic or reproductive conditions. Women with these diagnoses are better served by a specialist or a platform with dedicated OB-GYN or reproductive endocrinology coverage.

Superpower's Lab Panels: What Women Actually Get

Superpower's flagship lab panel is broad by telehealth standards. Reported markers include a comprehensive metabolic panel, complete blood count, lipid panel, thyroid panel (typically TSH plus free T3 and free T4), sex hormones (estradiol, testosterone, SHBG, progesterone, LH, FSH), inflammatory markers (hsCRP, homocysteine), vitamin D, iron studies, and HbA1c.

For most healthy women in their 30s and 40s who have not had this breadth of testing before, this panel can generate genuinely useful information. The Endocrine Society's clinical practice guidelines note that screening for thyroid dysfunction is appropriate in women with symptoms or risk factors, and that evaluation of androgen status requires context including menstrual history and clinical presentation.

Life-Stage Considerations for Lab Interpretation

Reproductive years (roughly ages 18 to 40): Estradiol, LH, FSH, and progesterone fluctuate across the menstrual cycle. A single measurement interpreted without knowing cycle day can be misleading. Superpower's intake process does ask for menstrual cycle information, but whether this consistently informs lab interpretation depends on the individual clinician reviewing your results. If your clinician does not note where you are in your cycle when interpreting your estradiol, the number is nearly meaningless.

Perimenopause (roughly ages 40 to 55, highly variable): FSH and estradiol become erratic, and a single lab snapshot is even less reliable as a decision-making tool. The Menopause Society (formerly NAMS) states explicitly that the diagnosis of perimenopause is clinical, based on symptoms and menstrual pattern changes, not on a single hormone level. A platform that treats your FSH as the primary decision point for hormone therapy may be oversimplifying your care.

Post-menopause: Sex hormone levels are consistently low, so the interpretive challenge is less about cycle timing and more about establishing a clinically appropriate baseline and monitoring therapy response. This is where a biomarker-forward platform can add more consistent value, provided the clinician is experienced with menopausal hormone therapy.

Trying to conceive: Superpower is not a fertility platform. If you are actively trying to conceive, you need ASRM-aligned fertility care, not a longevity optimization subscription.

Pregnancy, Lactation, and Contraception: Critical Information for Women

This section is not optional reading. Several medications that Superpower may prescribe carry pregnancy and lactation safety implications that every woman of reproductive age must understand before starting them.

Medications Commonly Prescribed Through Optimization Platforms

Testosterone (including compounded forms): Testosterone is FDA Category X in pregnancy, meaning it is contraindicated and known to cause fetal harm, specifically virilization of a female fetus. Any woman of reproductive age prescribed testosterone must use reliable contraception. This is a non-negotiable clinical standard, and any platform that prescribes testosterone without confirming contraceptive status is not meeting basic safety requirements.

DHEA: Data on DHEA in pregnancy is limited, but given its androgenic activity, it should be avoided in pregnancy and its safety in lactation is not established. Women who are breastfeeding should not take DHEA without specific clinician guidance supported by current evidence.

Metformin (sometimes prescribed for metabolic optimization or PCOS): Metformin is generally considered compatible with pregnancy and is sometimes continued through the first trimester in women with PCOS or type 2 diabetes per ACOG guidance. Limited transfer into breast milk is documented, and the NIH LactMed database considers it acceptable during lactation.

GLP-1 receptor agonists (semaglutide, tirzepatide, including compounded versions): These medications are contraindicated in pregnancy. Animal studies show fetal harm at exposures relevant to human doses. Women of reproductive age prescribed a GLP-1 must use effective contraception and discontinue at least two months before attempting pregnancy. Data in lactation is absent; avoidance is recommended. If you are prescribed a GLP-1 through Superpower or any telehealth platform, this conversation must happen explicitly with your clinician.

Thyroid medications (levothyroxine, compounded T3/T4 combinations): Thyroid hormone replacement is generally safe and often required in pregnancy. However, dosing changes in pregnancy, typically increasing by 25 to 50 percent, and requires close monitoring. ACOG and the American Thyroid Association recommend TSH monitoring every four to six weeks during pregnancy. A telehealth platform is not equipped to provide this level of ongoing obstetric-integrated monitoring. If you become pregnant while on thyroid medication through Superpower, transfer your care to an OB-GYN or maternal-fetal medicine specialist promptly.

Who This Platform May Work For, and Who It Does Not

May be a reasonable fit if you:

• Are a generally healthy adult woman aged 30 to 55 with no complex gynecologic conditions
• Have adequate health literacy to interpret nuanced lab results and question oversimplified recommendations
• Are not pregnant, not breastfeeding, and not actively trying to conceive
• Want broader baseline lab testing than your primary care physician currently offers
• Can afford $999 per year plus medication costs without financial strain
• Have a primary care physician or OB-GYN who can serve as your safety net for issues outside the platform's scope

Is likely a poor fit if you:

• Have PCOS, endometriosis, fibroids, or a history of hormone-sensitive cancer
• Are pregnant, planning pregnancy within 12 months, or breastfeeding
• Are in active perimenopause with complex or severe symptoms requiring nuanced hormone management
• Have postpartum thyroiditis or other autoimmune thyroid conditions
• Rely on this platform as your only source of medical care
• Have had difficulty with subscription cancellation in other contexts and cannot absorb the financial risk

How Superpower Compares to Other Women's Health Telehealth Options

The preventive and longevity telehealth space has expanded rapidly. Competitors include Parsley Health, Plume, Midi Health (menopause-specific), and Hers, among others. For women specifically:

• Midi Health focuses exclusively on perimenopause and menopause, with clinicians who specialize in menopausal hormone therapy. The Menopause Society's provider finder can help you identify NAMS-certified practitioners if you prefer in-person or platform-specific expertise.

• Parsley Health uses a functional medicine model with more individualized clinician time per visit and a stronger focus on female-pattern metabolic disease.

• Neither of these is a perfect solution either, and both carry their own evidence gaps and pricing concerns. The key differentiator is whether the platform's clinical model is built around women's physiology or retrofitted from a male-default or gender-neutral framework.

The Bottom Line on Value

At $999 per year, Superpower's membership costs roughly the same as two to three visits with a private concierge internist, but spreads that access across the year with ongoing lab monitoring. For a woman who has genuinely been unable to get comprehensive metabolic and hormone labs through her insurance-based primary care, this may represent real value.

The risk is that the "optimization" framing can create a sense of clinical authority that the platform's evidence base does not fully support. A 2023 analysis in JAMA Internal Medicine found that direct-to-consumer lab testing often generates incidental findings that lead to downstream testing and procedures without improving outcomes. For women, who already face higher rates of over-diagnosis in some conditions, this is a meaningful caution.

The price trajectory, moving upward from approximately $49 per month at launch to $99 per month within three years, suggests that early-adopter pricing was a customer acquisition strategy rather than a sustainable model. If current pricing continues on this trajectory, a membership that costs $999 today may cost $1,200 to $1,500 annually within two to three years.

Ask the platform, in writing, what its price lock policy is before you subscribe.